Jing Medicine Technology divulges new 5-HT2A receptor agonists

Sep. 5, 2025

Jing Medicine Technology (Shanghai) Ltd. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression.

Cancer

Jing Medicine Technology discloses new PROTACs for cancer

Dec. 14, 2022

Jing Medicine Technology (Shanghai) Ltd. has patented proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to ALK tyrosine kinase receptor- and/or epidermal growth factor receptor (EGFR)- and/or proto-oncogene tyrosine-protein kinase ROS (ROS1)-targeting moiety reported to be useful for the treatment of cancer.

Cancer

EED inhibitor HJM-353 shows antitumor activity in preclinical models of cancer

Sep. 19, 2022

Polycomb repressive complex 2 (PRC2) is composed of several subunits, such as EZH2, EED and SUZ12, and is a regulator of cell proliferation and development. Targeting the allosteric subunit EED may be a new approach for fully inhibiting PRC2 complex activity and addressing the limitations of EZH2 inhibition.

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...